Area of research
Oncology · Cancer Research
Research interest
Research interests include Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, and Cancer Cells and Metastasis.
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
758 GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens
A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy
Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis